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The A-kinase anchoring protein (AKAP) GSK3 interaction
protein (GSKIP) is a cytosolic scaffolding protein binding pro-
tein kinase A (PKA) and glycogen synthase kinase 3 (GSK3).
Here we show that both the AKAP function of GSKIP, i.e. its
direct interaction with PKA, and its direct interaction with
GSK3 are required for the regulation of -catenin and thus
Wnt signaling. A cytoplasmic destruction complex targets
-catenin for degradation and thus prevents Wnt signaling.
Wnt signals cause -catenin accumulation and translocation
into the nucleus, where it induces Wnt target gene expression.
GSKIP facilitates control of the-catenin stabilizing phosphor-
ylation at Ser-675 byPKA. Its interactionwithGSK3 facilitates
control of the destabilizing phosphorylation of-catenin at Ser-
33/Ser-37/Thr-41. The influence of GSKIP on -catenin is
explained by its scavenger function; it recruits the kinases away
from the destruction complex without forming a complex with
-catenin. The regulation of -catenin by GSKIP is specific for
this AKAP as AKAP220, which also binds PKA and GSK3, did
not affect Wnt signaling. We find that the binding domain of
AKAP220 for GSK3 is a conserved GSK3 interaction domain
(GID), which is also present inGSKIP.Our findings highlight an
essential compartmentalization of both PKA and GSK3 by
GSKIP, and ascribe a function to a cytosolic AKAP-PKA inter-
action as a regulatory factor in the control of canonical Wnt
signaling.Wnt signaling controls different biological processes,
including embryonic development, cell cycle progression, gly-
cogen metabolism, and immune regulation; deregulation is
associated with diseases such as cancer, type 2 diabetes, inflam-
matory, and Alzheimer’s and Parkinson’s diseases.
A-kinase anchoring proteins (AKAPs)3 are a family of about
50 scaffolding proteins. Their conserved function is the com-
partmentalization of protein kinase A (PKA). PKA holoenzyme
consists of a dimer of regulatory (RI, RI, RII, or RII) and
two catalytic subunits each bound to one R subunit. AKAPs
directly interact with R subunits and tether the kinase to
defined cellular compartments such as vesicles, the sarcoplas-
mic reticulum, or the cytoskeleton. This compartmentalization
confers a tight spatiotemporal control to PKA signaling, and
enables PKA to elicit a specific cellular response to each of the
many stimuli that cause cAMP elevation and thereby lead to
activation of this ubiquitous kinase. AKAPs directly interact
with further signaling proteins, thus mediating crosstalk
between signaling systems: phosphatases, dephosphorylating
PKA-phosphorylated substrates, adenylyl cyclases, synthesiz-
ing cAMP, and phosphodiesterases (PDEs), hydrolyzing cAMP.
Several AKAPs bind further kinases such as protein kinase C
(PKC), which are activated by signals other than cAMP, e.g.
Ca2. AKAPs and their interactions play key roles in a variety of
physiological processes such as vasopressin-mediated water
reabsorption in renal principal cells and cardiac myocyte con-
tractility (1–5, 7, 8).
A new example of an AKAP that mediates crosstalk is the
cytoplasmic GSK3 interaction protein (GSKIP). It binds PKA
and GSK3 (9). The ubiquitously expressed serine/threonine
protein kinase GSK3 is a component ofmultiple signaling sys-
tems such as canonical Wnt, insulin, Hedgehog, Notch, and
TGF signaling. GSK3 is constitutively active. It can be inac-
tivated by phosphorylation of Ser-9 by multiple kinases includ-
ing protein PKA (10), PKB (11), and p38MAPK (12). GSK3 is
involved in the regulation of different biological processes, e.g.
embryonic development, cell cycle progression, glycogen
metabolism, and immune regulation. Deregulation of GSK3 is
associated with pathologies such as cancer, type 2 diabetes,
bipolar disorder, cardiac hypertrophy inflammatory, and Alz-
heimer’s and Parkinson’s diseases (13–16). The diversity of
GSK3 functions is also reflected by its presence in different
cellular compartments; GSK3 is located in the cytosol, at the
plasmamembrane, in the nucleus, and inmitochondria (17, 18).
In canonical Wnt signaling, GSK3 assembles with Axin,
-catenin, adenomatous polyposis coli (APC), and casein
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kinase 1 (CK1) in the destruction complex in the cytosol. In the
absence of a Wnt signal, GSK3 phosphorylates Axin-bound
-catenin at Thr-41, Ser-33 and Ser-37 (19–23). This targets
-catenin for ubiquitination and proteasomal degradation and
inhibits Wnt signaling (24). Wnt signaling is activated by bind-
ing of Wnt ligands to receptor complexes at the plasma mem-
brane, consisting of LRP5/6 single-pass transmembrane pro-
tein and G protein-like receptors of the Frizzled (Fz) family.
The -catenin destruction complex is recruited to the LRP5/6
receptor, accompanied by an inhibition of degradation of
-catenin. Then -catenin accumulates and translocates into
the nucleus where it induces expression of Wnt target genes
(25, 26).
GSKIP seems able to induce -catenin accumulation in
the cytoplasm and the nucleus and to activate transcription
through direct interaction with GSK3 when overexpressed in
HeLa and neuroblastoma SH-SY5Y cells (27, 28). In SH-SY5Y
cells, the GSKIP overexpression blocked neurite outgrowth
during retinoic acid-mediated differentiation. Although the
data were obtained in cell systems overexpressing GSKIP, they
suggested that GSKIP acts as a regulator in canonical Wnt
signaling.
We observed that GSKIP facilitates the phosphorylation of
GSK3 by PKA at Ser-9 and thereby its inhibition (9), and that
GSKIP deficiency modulates this phosphorylation and thus
GSK3 activity during development (29). The loss of GSKIP in
mice causes a cleft palate, resembling the one inGsk3/mice
(30), and perinatal lethality through respiratory distress (29).
Knock-out of any of the subunits of PKA does not cause a cleft
palate. Thus GSKIP and GSK3 are crucial for normal cranio-
facial development. This most likely does not involve Wnt sig-
naling, as Wnt signals apparently do not influence phosphory-
lation of Ser-9 of GSK3 (31).
Here we show that GSKIP affects specific phosphorylations
of -catenin and thusWnt signaling through its direct interac-
tions with PKA and GSK3. To our knowledge, this is the first
time that a physiological function can be ascribed to a cytosolic
AKAP-PKA interaction.
Results
Endogenous GSKIP Regulates Wnt Signaling through Phos-
phorylation of -Catenin by PKA—The scaffolding protein
assembling the destruction complex is Axin. Axin exists in two
isoforms, Axin1 and Axin2: Axin1 is constitutively expressed,
and Axin2 expression is regulated through Wnt signaling (32,
33). GSK3 phosphorylates Axin-bound -catenin within the
destruction complex at Ser-33/Ser-37/Thr-41, targeting it for
proteasomal degradation. We initially examined whether
endogenous GSKIP influences the composition of the destruc-
tion complex.We knocked down GSKIP in HEK293 cells using
siRNA and immunoprecipitated endogenous GSK3 (Fig. 1).
As expected, GSK3 co-immunoprecipitated with Axin1 in the
presence of a control non-targeting siRNA (siNT). The
siRNA-mediated reduction of GSKIP increased the co-immu-
noprecipitation of GSK3 and Axin1, indicating that GSKIP
affects the composition of the complex by recruiting GSK3.
Next, we performed siRNA experiments to assess the role of
endogenousGSKIP in coordinating PKA inWnt signaling. PKA
phosphorylates -catenin at Ser-675 and thereby stabilizes the
protein (34, 35). Cytosols from HEK293, A549, and HeLa cells
were analyzed by Western blotting. In the absence of a Wnt
signal, the level of -catenin, unphosphorylated or phosphory-
lated at Ser-675, was low (Fig. 2, A–C). Wnt3a stimulation
increased -catenin expression, which was enhanced by the
knockdown of GSKIP. Thus the reduction of the scaffold
GSKIP apparently sets free the kinase, which then phosphory-
lates its substrate. Inhibition of PKA with the stearate-coupled
and thus membrane-permeant specific heat-stable PKA inhib-
itor peptide (PKI) or H89, either alone or in combination
with the GSKIP siRNA, inhibited the increase in Ser-675
phosphorylation.
To measure Wnt signaling activity, we performed Wnt
reporter assays using the TOPflash/FOPflash reporter system
(36). HEK293 cells were transfected with siRNAs together with
the reporter vectors and a vector encoding Renilla luciferase,
used as an internal standard. Luciferase activity was measured
48 h later. The measurements showed that the knockdown of
GSKIP and the associated increase in Ser-675 phosphorylation
caused an increase in luciferase activity, indicative of an
increase in -catenin-mediated transcription (Fig. 2D).
Binding of Wnt to its receptor causes phosphorylation of
LRP6 at Ser-1490 byGSK3, and other kinases. This phosphor-
ylation was not affected by the knockdown of GSKIP (Fig. 2E).
The knockdown also did not result in a significant change of the
level of Ser(P)-9 GSK3, indicating that Ser-9 is not involved in
control of GSK3 over Wnt signaling if GSKIP is reduced (Fig.
2E). In addition, GSKIP knockdown did not alter the phosphor-
ylation of -catenin at Ser-33/Ser-37/Thr-41 in the presence of
the proteasome inhibitor, MG-132 (Fig. 2F). MG-132 was used
to obtain signals in the Western blot as the phosphorylation
marks -catenin for proteasomal degradation. The actual
enrichment of cytosolic proteins in the cytosolic fraction used
for the experiments such as those depicted in Fig. 2, A–C, was
confirmed by Western blotting (Fig. 2G).
Direct Interactions of GSKIP with Both PKA and GSK3
Are Required for Control of Wnt Signaling under Resting
Conditions—To confirm the requirement of the direct interac-
tion between GSKIP and PKA for the control of -catenin, we
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FIGURE 1.GSKIP recruits GSK3 fromAxin. HEK293 cells were treated with
siRNA to knock down the expression of GSKIP (siGSKIP) or with control non-
targeting siRNA (siNT). GSK3 was immunoprecipitated, and GSK3 and co-
immunoprecipitated Axin1 were detected by Western blotting (WB). Signals
were semi-quantitatively analyzed by densitometry, and the ratio of precipi-
tated Axin1 to GSK3was calculated; n 4, mean S.E., ANOVA, *, p 0.05.
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generated a PKA-binding-deficient (GSKIP-N42I) variant of
GSKIP, and as a control, the previously describedGSK3-bind-
ing-deficient GSKIP variant, GSKIP-L130P (27, 37). We ini-
tially analyzed the interaction of the GSKIP variants with PKA
by cAMP-agarose precipitation. cAMP-agarose precipitates
regulatory subunits of PKA and the associated AKAPs. When
compared with the wild type and GSKIP-L130P, little GSKIP-
N42I was detectable in the precipitates, confirming its inability
to interact with PKA (Fig. 3A). To analyze binding of theGSKIP
variants to endogenousGSK3, tagged proteinswere expressed
in HEK293 cells. Endogenous GSK3 was immunoprecipi-
tated, and Western blotting was used to detect GSKIP or the
variants (Fig. 3B). Wild type GSKIP and GSKIP-N42I co-pre-
cipitated with GSK3, whereas GSKIP-L130P did not. Similar
experiments where GSKIP was immunoprecipitated via its
FLAG tag were also performed (Fig. 3C).
Only the wild type GSKIP triggered a significant increase in
basal -catenin-induced transcription, whereas no changes
were observed in the presence of the PKA-binding-deficient or
GSK3-binding-deficient variants of GSKIP (Fig. 3D). These
findings show that the interactions of GSKIP with both PKA
and GSK3 are required for -catenin-dependent transcrip-
tion under resting conditions.
Interactions of GSKIP with Both PKA and GSK3 Are
Required for Wnt-stimulated Transcriptional Activation
through -Catenin—HEK293 cells were transfected with
GSKIP, GSKIP-L130P, or GSKIP-N42I together with
TOPflash/FOPflash. Stimulation for 24 h with Wnt3a-condi-
tionedmedium increasedWnt signaling in the presence of wild
type GSKIP (Fig. 4A). Ablation of binding to either PKA or
GSK3 prevented the Wnt-induced transcription. We further
examined whether the PKA-binding-deficient GSKIP-N42I
would affect the PKA phosphorylation of -catenin (Fig. 4, B
and C). Surprisingly, and in contrast to the increase in Ser-675
phosphorylation if GSKIP was down-regulated, the loss of PKA
binding to GSKIP did not alter the phosphorylation of Ser-675
in the presence of Wnt. We also investigated the influence of
GSKIP on Wnt signaling following stimulation with recombi-
nant Wnt3a in a concentration-dependent manner for 24 h.
Wnt3a and GSKIP expression activated Wnt signaling addi-
tively (Fig. 4D).
We inhibited the proteasomal degradation of proteins with
MG-132 usingHEK293 cells that expressed theGSKIP variants.
MG-132 increased the levels of -catenin phosphorylated at
Ser-33/Ser-37/Thr-41 (19, 38) and of-catenin (Fig. 5A). How-
ever, only in the presence of wild type GSKIP, Ser(P)-33/Ser-
37/Thr-41 -catenin was reduced significantly and cytosolic
-catenin increased (Fig. 5, A and B).
Thus collectively, it appears that GSKIP must interact with
both kinases to regulateWnt-dependent transcription through
-catenin. It involves phosphorylation of Ser-33/Ser-37/
Thr-41 and Ser-675 of -catenin by GSK3 and PKA, respec-
tively. When GSKIP expression is knocked down, i.e. probing
the endogenous role of GSKIP, the mode of action is indepen-
dent from the previously observed Ser-9 phosphorylation of
GSK3 by PKA, which GSKIP facilitates (9). GSKIP and
-catenin did not co-immunoprecipitate, indicating that stable
complex formation of the two proteins is not required for the
observed GSKIP-mediated control of -catenin phosphoryla-
tion (Fig. 5C).
GSKIP-dependent Regulation of -Catenin Is Specific for this
AKAP—Besides GSKIP, two other AKAPs, MAP2 and
AKAP220 (AKAP11), bind both PKA and GSK3 (9, 39–41).
AKAP220 and GSKIP both facilitate phosphorylation of
GSK3 at Ser-9 by PKA and thus inhibition of GSK3 (9, 39).
The binding sites for PKA are conserved within the AKAP fam-
ily. The site in AKAP220 was previously mapped (41). We
examined whether AKAP220 binds GSK3 in a similar way as
otherGSK3-interacting proteins, namely by aGSK3 interac-
tion domain (GID). AKAP220 binds GSK3 directly in a region
that spans amino acid residues 1017–1386 (39). We performed
protein sequence alignment of mammalian Axin1/2, GSKIP,
and AKAP220, which suggested a putative GID in this region,
because they show strong conservation among the homologs
and contain central FLL motifs that are identical at the critical
positions (Fig. 6A). In addition, themotif was predicted to form
an -helix, as is true of other GIDs (42). We spot-synthesized
this region of AKAP220 as 25-mer overlapping peptides and
investigated interactions of the peptides with recombinant
GST-GSK3 that had been pre-exposed to peptides represent-
ing the GSK3-binding domain of GSKIP (GSKIPtide) or with
the GSK3-binding-deficient variant GSKIPtide-L130P (9, 27)
(Fig. 6B). Remarkably, binding of GSK3 to spots A8, A9, and
A10 of human AKAP220 was observed in the presence of
GSKIPtide-L130P, but binding was strongly reduced in the
presence of GSKIPtide.We performed alanine scans to identify
single amino acid residues of theAKAP220GID that contribute
to GSK3 binding (Fig. 6C). Substitutions revealed that Phe-
1162, Leu-1166, and Leu-1170 were each essential for binding.
This shows that as in Axin1/2 and GSKIP, an FLL motif within
the GID of AKAP220 is required for the interaction with
GSK3.
GSKIP, Axin, and AKAP220 Compete for GSK3 Binding—
Differently tagged GSK3, AKAP220, Axin1, GSKIP, and com-
binations thereof were produced in HEK293 cells, followed by
co-immunoprecipitation andWestern blotting. GSK3 precip-
FIGURE 2. EndogenousGSKIP enhancesWnt signaling through controlling PKAphosphorylation of-catenin at Ser-675.HEK293, A549, andHeLa cells
were left untreated or treated as indicatedwith siRNA to knock downGSKIP (siGSKIP), control siRNA (siNT), Wnt3a-enrichedmedium, or control medium in the
absenceor presenceof the PKA inhibitors, PKA inhibitor peptide (PKI) orH89, or theproteasome inhibitorMG-132.A–C, cytosol fractionswerepurified from the
three cell types and analyzed by Western blotting (WB) for expression of the indicated proteins. The signals were densitometrically analyzed, and ratios of
-catenin/GAPDH and Ser(p)675--catenin/GAPDH were calculated; n 6, mean S.E., ANOVA, **, p 0.01, ***, p 0.001. D, TOPflash/FOPflash (TOP/FOP)
luciferase assay. HEK293 cells were stimulatedwithWnt-enriched or controlmedium; n 4,mean S.E., ANOVA, **, p 0.01. E, cell lysateswere purified from
HEK293 cells, and the indicated proteins were detected byWestern blotting. Semi-quantitative densitometric analysis ofWestern blots is depicted as ratios of
Ser(P)1490LRP6/GAPDHandSer(P)9GSK3/GAPDH;n6,meanS.E., ANOVA, *,p0.05, ***,p0.001. F, cytosolic fractionswerepurified, and the indicated
proteins were detected by Western blotting. Semi-quantitative densitometric analysis of Western blots shows the ratios of -catenin/GAPDH and (Ser(P)33/
Ser-37/Thr-41)--catenin/GAPDH;n6,mean S.E., ANOVA, ***,p0.001.pS33/S37/T41, Ser(P)33/Ser-37/Thr-41.G, the enrichmentof the indicatedproteins
in thecytosolic fractionsofHEK293cells thatwereused inAwasconfirmedbyWesternblotting. Thecellswere treatedwithWnt3a-enrichedor controlmedium.
Shown are representative blots from n 4 experiments.
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itated with AKAP220, Axin, and GSKIP (Fig. 7A). The level of
AKAP220 was reduced upon co-expression of Axin1, and
GSKIP co-expression strongly diminished the AKAP220 level.
Co-immunoprecipitated AKAP220 was then calculated as the
ratio to the input of the competitors, which was reduced when
cells co-expressed Axin1 and even more so with GSKIP (Fig.
7A). We then examined whether GSKIP competes with
Axin1/2 for GSK3 binding by co-immunoprecipitation and
Western blotting, asGSKIP andAxin1/2 share a commonmotif
for binding GSK3 (Fig. 7B) (27). In cells expressing Axin1 or
Axin2, the amount of GSKIP bound to GSK3was significantly
reduced (Fig. 7B). These results indicate thatAKAP220,GSKIP,
andAxin1 compete for the binding ofGSK3. As these proteins
may assemble with GSK3 in different cellular compartments,
Axin, AKAP220, andGSKIPmight establish functionally differ-
ent pools of GSK3.
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GSKIP andAKAP220 Play Different Roles inWnt Signaling—
We compared the influence of GSKIP and AKAP220 on -
catenin-dependent transcription. Fig. 3D shows that only
GSKIP activated the luciferase reporter system inHEK293 cells
under resting conditions. In HEK293 cells stimulated for 4 h
with Wnt, only GSKIP enhanced the reporter system but not
AKAP220 (Fig. 4A). The cytosolic fractions of untreated
HEK293 cells and cells treated with Wnt3a were enriched, and
-catenin levels were monitored by Western blotting (Fig. 8).
These levels were strongly increased in the Wnt-stimulated
samples. The effect of Wnt on -catenin levels significantly
increased in the presence of GSKIP, but not in the presence of
AKAP220. As in the presence of elevated levels of GSKIP (Fig.
4), the elevation of AKAP220 levels did not affect the phos-
phorylation of Ser-675 of -catenin (Fig. 8). Axin1 up-regu-
lation was observed upon expression of wild type GSKIP in
unstimulated cells but not in the presence of AKAP220. This
was not seen upon Wnt stimulation. Thus GSKIP and
AKAP220 exert different effects on -catenin, although both
bind GSK3 and PKA. This suggests that they control differ-
ent pools of GSK3 and PKA that influence the Wnt signal-
ing destruction complex in different ways.
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Discussion
Our findings demonstrate that GSKIP regulates Wnt signal-
ing through its direct protein-protein interactions with both
GSK3 and PKA. The two GSKIP-bound kinases differentially
modulate the phosphorylation and thereby the stability of
-catenin (Fig. 9). GSKIP apparently has a “scavenger” activity
for GSK3 and PKA that is independent of a direct interaction
of GSKIP with the destruction complex. Instead, GSKIP estab-
lishes an independent GSK3/PKA pool.We observed a role of
GSKIP in Wnt signaling in three different cell lines. The ubiq-
kDa
37-
GAPDH
pS33/S37/T41
β-catenin100-
GSKIP
20-
FL
AG
-G
SK
IP
 W
t
ve
cto
r c
on
tro
l
++
FL
AG
-G
SK
IP
 N
42
I
FL
AG
-G
SK
IP
 L
13
0P
MG-132 ++
FL
AG
-G
SK
IP
 W
t
ve
cto
r c
on
tro
l
FL
AG
-G
SK
IP
 N
42
I
FL
AG
-G
SK
IP
 L
13
0P
A
20 -
37 -
100 -
GAPDH
GSKIP
100 - β-catenin
pS33/S37/T41
β-catenin 
FLAG-GSKIP+ +
MG-132++
vector control+ +
β-
ca
te
ni
n/
G
A
P
D
H
1.0
0
0.5
1.5
vector control + +
FLAG-GSKIP + +
MG-132 + +
***
***2.0
2.5
***
pS
33
/S
37
/T
41
 β
-c
at
en
in
/G
A
P
D
H
1.0
0
0.5
1.5 **
***
***
B
GAPDH
FLAG-GSKIP
FLAG-GSKIP
β-catenin
β-catenin
37 -
20 -
100 -
kDa
20 -
100 -
WBIP: FLAG
Input
FL
AG
-G
SK
IP
-W
t
ve
cto
r c
on
tro
l
C
kDa
0
1
2
3
pS
er
33
 β
-c
at
en
in
/G
A
P
D
H
FL
AG
-G
SK
IP
 W
t
ve
cto
r c
on
tro
l
FL
AG
-G
SK
IP
 N
42
I
FL
AG
-G
SK
IP
 L
13
0P
++MG-132 ++
FL
AG
-G
SK
IP
 W
t
ve
cto
r c
on
tro
l
FL
AG
-G
SK
IP
 N
42
I
FL
AG
-G
SK
IP
 L
13
0P
**
**
******
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FIGURE 6. GSK3 binds AKAP220 at a conserved GID. A, alignment of the GIDs from the indicated human (Hs), rat (Rn), and mouse (Mm) proteins, and
prediction of AKAP220 three-dimensional structure in the 1162–1176 region through secondary structure analysis using PSIPRED at the University
College London (UCL) Department Of Computer Science. aa, amino acid. B, amino acid residues 1017–1386 of AKAP220 were spot-synthesized as
25-mer overlapping peptides and overlaid with GST alone or with GST-GSK3 that was pre-incubatedwith either the inactive control peptide GSKIPtide-
L130P or the peptide GSKIPtide, which blocks the interaction of GSK3 with spot-synthesized peptides. Interaction of GSK3 with peptides was
detected using anti-GSK3 antibodies. The sequences of the GSK3-binding peptides in positions A8–A10 of the peptide array are shown. The
sequence common in all three peptides is highlighted. C, the GID of AKAP220, amino acids 1155–1179, was spot-synthesized as 25-mer peptides (wild
type (wt)) or as peptideswhere each amino acidwas substituted by an alanine. The peptideswere overlaidwith recombinant GSK3, and interactionwas
detected using anti-GSK3 antibodies.
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uitous expression of all three, GSKIP, GSK3, and PKA, sug-
gests that the complex regulates canonical Wnt signaling in a
broad range of physiological and disease contexts in which the
pathway has been implicated.
MostAKAPs possess unique targeting domains, which direct
the AKAP-PKA complex to defined cellular compartments
including membranes, cytoskeletal components, or other
structures (2, 3, 44, 45). Some AKAPs, however, lack canonical
targeting domains. They can both reside in the cytosol and con-
stitutively associate with other compartments, or they can
reside in the cytosol and reversibly associate with other com-
partments through dynamic regulatory mechanisms. For
example, AKAP18 is a cytosolic protein, but positively
charged amino acids distributed across its surface permit it to
associate with membrane lipids in renal collecting duct princi-
pal cells (46, 47). The AKAPGravin is released from the plasma
membrane into the cytosol in response to an elevation of intra-
cellular calcium in HEC-1A endometrial cancer cells (48).
GSKIP is cytosolic (Fig. 2G) (9), and there is no evidence of a
stimulus-dependent redistribution to another compartment.
Its location is not altered, for example, by retinoic acid (28), an
elevation of cAMP (9), or Wnt stimulation. Thus for the first
time, our data ascribe a physiological function to a strictly cyto-
solic AKAP-PKA interaction. Based on the conservation and
ubiquitous expression ofGSKIP (9), the interaction presumably
plays a role in Wnt signaling in many types of cells. Because
GSKIP is an RII-specific AKAP (9),Wnt signalingmust be con-
trolled by PKA type II, the PKA that contains RII subunits. PKA
is involved in the control ofWnt signaling in various processes.
For example, parathyroid hormone stimulation promotes
osteoblast differentiation, a process that involves phosphoryla-
tion of LRP5/6 by PKA (49), and PKA-dependent phosphoryla-
tion and thus inhibition of GSK3 (50). Whether such pro-
cesses require an interaction between PKA and AKAPs, and
specifically with GSKIP, remains to be determined.
We askedwhether the effects observed forGSKIP are specific
for this one AKAP, or whether an effect on Wnt signaling can
also be achieved through a simple scaffolding of PKA and
GSK3 by another AKAP such as AKAP220. GSKIP and
AKAP220 differ in their cellular location: GSKIP is cytoplasmic
(9, 27), whereas AKAP220 is predominantly found at the
plasma membrane and on peroxisomes (41, 51–53). GSKIP
does not interact with -catenin, whereas AKAP220 forms a
complexwith-catenin and cadherin at the plasmamembrane,
which competes for -catenin in Wnt signaling (51, 54). How-
ever, a direct competition would affect Wnt signaling activity
and cytosolic -catenin levels. This effect does not seem to
explain our observations and emphasizes the neutrality of
AKAP220 in Wnt signaling. This is also in line with observa-
tions that the role of the AKAP220-cadherin complex in endo-
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thelial barrier function is independent of Wnt signaling (51).
These effects can best be explained by the fact that the two
AKAPs are localized to different cellular compartments, which
most likely leads to distinct pools of GSK3 that are regulated
in different ways. This would explain why AKAP220, in con-
trast to GSKIP, does not influence the availability of GSK3 for
the cytoplasmic destruction complex.
Here we also show that a common GID mediates the inter-
action ofAKAP220,Axin1/2, andGSKIPwithGSK3. A crystal
structure of the complex of GSK3 with the GID of Axin has
revealed the molecular determinants of this interaction (PDB:
1O9U) (42). The GID of Axin forms an amphipathic helix
whose hydrophobic face docks into a hydrophobic groove on
the surface of GSK3. Like Axin 1/2 and GSKIP, the GID of
human AKAP220 contains an FLL motif and thus is likely to
interact with GSK3 in a similar way. The presence of the GID
domain explains the competition between Axin1/2, AKAP220,
andGSKIP for binding toGSK3 and provides further evidence
that the scaffolding proteins define distinct pools of this kinase.
An additional motif was recently discovered in a nearby region
in AKAP220, identifying Thr-1132, which can be phosphory-
lated by GSK3 itself to permit binding (41). However, a previ-
ous study demonstrated binding between kinase-dead GSK3
and AKAP220 (39), which suggests the existence of further
points of contact betweenAKAP220 andGSK3 (41), likely the
FLL motif we identified.
By adding a new level to our understanding ofWnt signaling
control, our findings may have important clinical implications.
IncreasedWnt signaling activity plays a role in various cancers,
neurological diseases, fibrosis, and other diseases (55, 56). A
duplication of the chromosomal region encoding GSKIP pre-
disposes to myeloid lymphoma, presumably due to increased
GSKIP protein, inhibition ofGSK3, and increasedWnt signal-
ing (57). A general challenge in targeting the Wnt signaling
pathway for therapeutic purposes is its complex crosstalk with
MAPK, bonemorphogenetic protein (BMP),Hedgehog,Notch,
cAMP/PKA, and other pathways (50, 56, 58, 59). Targeting
GSK3 itself is equally challenging as it would likely cause side
effects due its broad involvement in several of these pathways.
An optionmight be to displace a specific pool of GSK3 from a
cellular compartment where it has specific, undesirable effects
onWnt signaling. GSKIP, AKAP220, and Axin establish differ-
ent pools of GSK3, but GSK3 interacts with further proteins
including MAP2, FRAT1, -2, and -3, and DISC1. Our work
opens a door on understanding the interplay of these GSK3
interactions with regard to Wnt signaling. The interaction of
GSKIP with GSK3 in the cytosol increases Wnt signaling. It
would be worthwhile to evaluate the therapeutic potential of
pharmacological interference with this interaction, because
GSKIP is up-regulated in breast cancer, melanoma, and other
forms of cancer that also exhibit a deregulation of Wnt signal-
ing. Targeting AKAP-dependent protein-protein interactions
is feasible and may be a novel approach in the treatment of
various diseases (7, 45, 60).
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FIGURE 9. Model of GSKIP-directed regulation of -catenin and thus of
Wnt signaling. GSKIP directly binds GSK3 and PKA. It controls the stability
of -catenin and thus its transcriptional activity through facilitating its phos-
phorylation (indicatedby circled P) by the twokinases. GSK3phosphorylates
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Experimental Procedures
GSKIP Variants—Mutagenesis was carried out using a
pECFP-GSKIP plasmid (9) with the QuikChange II Site-Di-
rected Mutagenesis Kit (Agilent) according to the manufactu-
rer’s recommendation. To prevent the interaction of GSKIP
with PKA, asparagine 42 was replaced by isoleucine. To gener-
ate a GSKIP variant deficient for binding of GSK3, leucine 130
was replaced by proline (37). The following primers were used:
N42IFwd, CTC GAA GCT GAA GCA GTT GTA AAT GAT
GTT CTC TTT GCT; N42IRev, TCG TTT CTC TTG TAG
TAA ATG TTG ACG AAG TCG AAG CTC; L130PFwd, CGC
ACT GCT TCA AAG ACC GGA AGC TTT GAA AAG AG;
and L130PRev, CTC TTT TCA AAG CTT CCG GTC TTT
GAA GCA GTG CG, thus generating the plasmids pECFP-
GSKIP-N42I and pECFP-GSKIP-L130P. The cDNAs were
cloned into pCMV6ev (OriGene) to generate the vectors
pCMV6-GSKIP-FLAG, pCMV6-GSKIP-L130P-FLAG, and
pCMV6-GSKIP-N42I-FLAG.
Cell Culture, Transfection, and Fractionation—HEK293,
A549, and HeLa cells were grown in DMEM (GlutaMAX, 10%
FCS, Thermo Fisher Scientific) and transfected with the above
mentioned plasmids, the vectors pECFP, pEYFP, pEYFP-
GSK3, p	ECFP-Myc-GSKIP (CFP deleted), pcDNA3.1-
FLAG-Axin1, pcDNA3.1-FLAG-Axin2, TOPflash, FOPflash,
pRL-SV40, and pCGN-HA-AKAP220 (kindly provided by K.
Taskén, The Biotechnology Centre of Oslo, University of Oslo,
Norway), SMARTpool siGENOME GSKIP siRNA, and
siGENOME Non-Targeting siRNA #2 (GE Healthcare, Chalf-
ont StGiles, UK) using Lipofectamine2000 (Thermo Fisher Sci-
entific) (9).
For cell fractionation and cytosol purification, a digitonin
semi-permeabilization protocol was adapted (61). Briefly,
HEK293 cells were treated with Wnt-enriched or control
medium for 4 h, washed twice with PBS, and semi-permeabi-
lizedwithDigitonin (61). The lysis buffer containing the cytosol
was cleared by centrifugation (supernatants; 5,000 g, 5 min).
The adherent, permeabilized cells were washed twice with PBS
and lysed in radioimmunoprecipitation assay buffer. Purity of
the cytosolic fractions was confirmed byWestern blotting with
antibodies directed against pan-Cadherin, LaminA/C and
GAPDH.
Immuno- and cAMP-Agarose Precipitations, and Western
Blotting—Immunoprecipitations were carried out as described
(9, 46). Cellswere lysed in standard lysis buffer (10mMK2HPO4,
150mMNaCl, 5mMEDTA, 5mMEGTA, 1%TritonX-100, 0,2%
sodium deoxycholate, pH 7.4) containing protease inhibitors
(cOmplete; RocheApplied Science, Rotkreuz, Switzerland) and
phosphatase inhibitors (PhosSTOP, Roche Applied Science).
The lysates were cleared by centrifugation (20,000  g, 4 °C,
10 min). Proteins were immunoprecipitated with anti-GFP
(62, 63) or anti-GSK3 (L-17, Goat, Santa Cruz Biotechnol-
ogy, Dallas, TX) antibodies, and protein A-conjugated aga-
rose (Sigma-Aldrich) or anti-FLAG-coupled magnetic beads
(Sigma-Aldrich).
As described previously (9), for cAMP-agarose precipita-
tions, the lysates were incubated with 8-AHA-cAMP-agarose
(4 °C, 3 h; BioLog, Bremen, Germany). Agarose-bound pro-
teins were washed four times with lysis buffer and eluted with
Laemmli sample buffer.
Western blotting was carried out as described (9, 46). The
following antibodieswere used:HSP90mouse (AC88; EnzoLife
Sciences, Lörrach, Germany); GFP mouse (JL-8; Takara Bio
Inc., Shiga, Japan); GFP-01, rabbit (custom-made (62)); GSKIP,
rabbit, (custom-made (9)); LaminA/C, goat (N-18; Santa Cruz
Biotechnology); HA High Affinity, rat (3F10; Roche Applied
Science); FLAG (M2), mouse and pan-Cadherin, mouse (Sig-
ma-Aldrich); Axin1 (C7B12), rabbit; Myc tag (9B11), rabbit;
GAPDH (H-12), rabbit; GSK3 (27C10), rabbit; phospho-
GSK3 (S9), rabbit; phospho--catenin (S675), rabbit;
-catenin (#9562), rabbit; and phospho--catenin (Ser-33/Ser-
37/Thr-41), rabbit (all from Cell Signaling, Cambridge, UK);
and RII antibody (mouse, BD Biosciences). Signals were
detected using EMD Millipore Immobilon Western Chemilu-
minescent HRP Substrate (Thermo Fisher Scientific) and an
Odyssey Fc Imaging System (LI-COR Biotechnology, Lincoln,
NE).
Peptide Spot Synthesis and Overlay with Recombinant
GSK3—25-mer peptides were spot-synthesized as described
using an Intavis ResPep SL spot synthesizer (Intavis, Cologne,
Germany) and incubated with a recombinant fusion protein of
GSK3 and glutathione S-transferase (GST; Cell Signaling; 1
g/ml) or GST alone (9, 43, 64, 65).
Luciferase Assays—HEK293 cells were transfected with plas-
mids encoding theGSKIP variants togetherwith pRL-SV40 and
TOPflash or FOPflash vectors and stimulated with recombi-
nant human Wnt3a (R&D Systems, Minneapolis, MN) or
Wnt3a-conditioned medium 24 h after transfection (6). The
cells were lysed 24 h later, and luciferase activity was measured
using the Dual-Luciferase Assay Kit (Promega, Fitchburg, WI)
and aCentroXS3LB960 luminometer (BertholdTechnologies,
Bad Wildbad, Germany). Luciferase activity was induced by
binding of -catenin to the reporter system. Activity of the
TOPflash and FOPflash vectors was normalized to activity of
the pRL-SV40 vector, and normalized TOPflash activity
was divided by the normalized FOPflash activity to obtain a
TOPflash/FOPflash ratio. For siRNA experiments, 24 h after
knockdown of GSKIP, the cells were transfected a second time
with the reporter vectors. After an additional 24 h, the cells
were stimulated for a further 24 h with Wnt3a-conditioned
medium.
Statistical Analysis—GraphPad Prism 5.0 (GraphPad Soft-
ware) was used to perform statistical analyses.
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